10X Genomics Inc (TXG : NASDAQ)
Common Stock
$84.11
USD
+8.49 (11.23%)
Last updated: 2026-09-24
Follow TXG
TXG
10X Genomics Inc
WealthAwesomePerformance
1 Day
+11.23%
1 Week
+9.28%
1 Month
+29.96%
YTD
+161.78%
Key Statistics
Market Cap
$10.96B
52W High
$85.93
52W Low
$11.16
P/E Ratio
-
50 Day MA
$59.54
200 Day MA
$32.57
Beta
2.08
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/24/2026 | $75.50 | $85.93 | $74.60 | $84.11 | $84.11 | 4,096,815 |
| 9/23/2026 | $80.37 | $81.93 | $74.75 | $75.62 | $75.62 | 3,476,541 |
| 9/22/2026 | $79.42 | $82.68 | $77.50 | $80.70 | $80.70 | 3,890,700 |
| 9/21/2026 | $79.15 | $80.11 | $76.73 | $79.10 | $79.10 | 2,447,270 |
| 9/18/2026 | $77.64 | $78.08 | $75.21 | $76.60 | $76.60 | 2,885,000 |
| 9/17/2026 | $75.38 | $79.94 | $75.00 | $76.97 | $76.97 | 3,141,237 |
| 9/16/2026 | $74.50 | $77.87 | $71.44 | $72.68 | $72.68 | 4,076,666 |
| 9/15/2026 | $70.13 | $75.61 | $70.11 | $74.39 | $74.39 | 2,905,279 |
| 9/14/2026 | $67.04 | $70.46 | $64.73 | $70.11 | $70.11 | 3,364,058 |
| 9/11/2026 | $67.40 | $69.67 | $67.00 | $68.59 | $68.59 | 1,829,696 |
Analyst Price Targets
Based on 16 analysts covering TXG · as of Sep 23, 2026
Wall Street analysts forecast TXG stock price to fall 32.7% over the next 12 months.
Consensus
Buy3.75 / 5.00
Avg. Target
US$56.60
-32.7% Upside
Previously US$52.13 on Sep 17, 2026
Current Price
US$84.11
Last close
Analyst Breakdown (16 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TXG's historical volatility
30-Day Vol
65.0%
Annualized
90-Day Vol
73.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$100.55
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$89.27 | US$71.33 – US$111.72 |
| 60 trading days | US$94.74 | US$68.99 – US$130.12 |
| 90 trading days | US$100.55 | US$68.18 – US$148.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About 10X Genomics Inc
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Financials
- Revenue (TTM)
- $616.91M
- EBITDA
- $-41.20M
- Profit Margin
- -12.18%
- ROE (TTM)
- -9.40%
- EPS (Diluted)
- -0.66
- Book Value
- 6.34
Classification
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About TXG.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| RPGL | Republic Power Group Limited Class A Ordinary Shares | $14.69 | +1363.23% |
| KITT | Nauticus Robotics Inc. | $2.93 | +459.21% |
| ZWZZT | NASDAQ TEST STOCK | $24.50 | +144.51% |
| SRZN | Surrozen Inc | $33.68 | +108.42% |
| GLND | Greenland Energy Company Common Stock | $5.35 | +83.85% |
| PMAX | Powell Max Limited Class A Ordinary Shares | $1.65 | +80.62% |
| STAK | STAK Inc. Ordinary Shares | $1.44 | +53.19% |
| PFSA | Profusa, Inc. Common Stock | $3.03 | +47.80% |
TXG.US news timeline
1 article covering TXG.US, most recent first
Latest